Publications by authors named "Hilde Revets"

Claim this Profile
E
Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence.
Ming Te Yeh, Erika Bujaki, Patrick T Dolan, Matthew Smith, Rahnuma Wahid, Hilde Revets

Cell Host Microbe· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poliopolis: pushing boundaries of scientific innovations for disease eradication.
Pierre Van Damme, Ilse De Coster, Ananda S Bandyopadhyay, Leen Suykens, Patrick Rudelsheim, Hilde Revets

Future Microbiol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.
Pierre Van Damme, Ilse De Coster, Ananda S Bandyopadhyay, Hilde Revets, Kanchanamala Withanage

Lancet· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poliopolis.
Pierre Van Damme, Ilse De Coster, Hilde Revets, Ananda S Bandyopadhyay

Lancet· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.
Marek Pruszynski, Eftychia Koumarianou, Ganesan Vaidyanathan, Hilde Revets, Nick Devoogdt

J Nucl Med· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.
Marek Pruszynski, Eftychia Koumarianou, Ganesan Vaidyanathan, Hilde Revets, Nick Devoogdt

Nucl Med Biol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy.
Maria J W D Vosjan, Jo Vercammen, Joost A Kolkman, Marijke Stigter-van Walsum, Hilde Revets

Mol Cancer Ther· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The development of nanobodies for therapeutic applications.
Femke Van Bockstaele, Josefin-Beate Holz, Hilde Revets

Curr Opin Investig Drugs· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression.
Lieven Huang, Lea Olive Tchouate Gainkam, Vicky Caveliers, Chris Vanhove, Marleen Keyaerts, Hilde Revets

Mol Imaging Biol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
Lea Olive Tchouate Gainkam, Lieven Huang, Vicky Caveliers, Marleen Keyaerts, Sophie Hernot, Hilde Revets

J Nucl Med· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attachment of the outer membrane lipoprotein (OprI) of Pseudomonas aeruginosa to the mucosal surfaces of the respiratory and digestive tract of chickens.
Karolien Loots, Hilde Revets, Bruno Maria Goddeeris

Vaccine· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A.
Tatiana Gartner, Martijn Baeten, Samuel Otieno, Hilde Revets, Patrick De Baetselier

Immunol Lett· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.
Rob C Roovers, Toon Laeremans, Lieven Huang, Severine De Taeye, Arie J Verkleij, Hilde Revets

Cancer Immunol Immunother· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The tumor-promoting effect of TNF-alpha involves the induction of secretory leukocyte protease inhibitor.
Nick Devoogdt, Hilde Revets, Anne Kindt, Yuan Qing Liu, Patrick De Baetselier

J Immunol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis.
Ken Coppieters, Torsten Dreier, Karen Silence, Hans de Haard, Marc Lauwereys, Hilde Revets

Arthritis Rheum· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and functionality of lipoprotein OprI from Pseudomonas aeruginosa as adjuvant for a subunit vaccine against classical swine fever.
Henriette Rau, Hilde Revets, Pierre Cornelis, Anja Titzmann, Nicolas Ruggli

Vaccine· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunological properties of recombinant classical swine fever virus NS3 protein in vitro and in vivo.
Henriette Rau, Hilde Revets, Carole Balmelli, Kenneth C McCullough, Artur Summerfield

Vet Res· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The wild-derived inbred mouse strain SPRET/Ei is resistant to LPS and defective in IFN-beta production.
Tina Mahieu, Jin Mo Park, Hilde Revets, Bastian Pasche, Andreas Lengeling

Proc Natl Acad Sci U S A· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses.
Hilde Revets, Gwenda Pynaert, Johan Grooten, Patrick De Baetselier

J Immunol· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanobodies as novel agents for cancer therapy.
Hilde Revets, Patrick De Baetselier, Serge Muyldermans

Expert Opin Biol Ther· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secretory leukocyte protease inhibitor in cancer development.
Nick Devoogdt, Hilde Revets, Gholamreza Hassanzadeh Ghassabeh, Patrick De Baetselier

Ann N Y Acad Sci· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient cancer therapy with a nanobody-based conjugate.
Virna Cortez-Retamozo, Natalija Backmann, Peter D Senter, Ullrich Wernery, Patrick De Baetselier, Hilde Revets

Cancer Res· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm.
Benoit Stijlemans, Katja Conrath, Virna Cortez-Retamozo, Hoang Van Xong, Lode Wyns, Hilde Revets

J Biol Chem· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells.
Nick Devoogdt, Gholamreza Hassanzadeh Ghassabeh, Jing Zhang, Lea Brys, Patrick De Baetselier, Hilde Revets

Proc Natl Acad Sci U S A· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient tumor targeting by single-domain antibody fragments of camels.
Virna Cortez-Retamozo, Marc Lauwereys, Gholamreza Hassanzadeh Gh, Martine Gobert, Katja Conrath, Hilde Revets

Int J Cancer· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis